front cover of Containing Addiction
Containing Addiction
The Federal Bureau of Narcotics and the Origins of America's Global Drug War
Matthew R. Pembleton
University of Massachusetts Press, 2017
The story of America's "War on Drugs" usually begins with Richard Nixon or Ronald Reagan. In Containing Addiction, Matthew R. Pembleton argues that its origins instead lie in the years following World War II, when the Federal Bureau of Narcotics—the country's first drug control agency, established in 1930—began to depict drug control as a paramilitary conflict and
sent agents abroad to disrupt the flow of drugs to American shores.

U.S. policymakers had long viewed addiction and organized crime as profound domestic and trans-national threats. Yet World War II presented new opportunities to implement drug control on a global scale. Skeptical of public health efforts to address demand, the Federal Bureau of Narcotics believed that reducing the global supply of drugs was the only way to contain the spread of addiction. In effect, America applied a foreign policy solution to a domestic social crisis, demonstrating how consistently policymakers have assumed that security at home can only be achieved through hegemony abroad. The result is a drug war that persists into the present day.
[more]

front cover of White Market Drugs
White Market Drugs
Big Pharma and the Hidden History of Addiction in America
David Herzberg
University of Chicago Press, 2020
The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs, David Herzberg explores these crises and the drugs that fueled them, from Bayer’s Heroin to Purdue’s OxyContin and all the drugs in between: barbiturate “goof balls,” amphetamine “thrill pills,” the “love drug” Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls “white markets,”  where legal drugs called medicines are sold to a largely white clientele.

These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its “drug wars”—until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America’s divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction.
Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century.

By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself—ideas that have been failing us catastrophically for over a century.
[more]


Send via email Share on Facebook Share on Twitter